Scientists discover how breast cancer cells evade treatment

have discovered how breast cancer cells can evade treatment by “hibernating” and then “wake up” years later – causing a relapse that is more difficult to treat.

Researchers from The Institute of Cancer Research in London have uncovered the mechanism by which the hormone treatment used to prevent breast cancer from returning triggers changes in some cancer cells, causing them to “hibernate” instead of dying off.

But scientists say there may be a way to target these “sleeping” cells before they wake up, offering hope for patients with oestrogen receptor positive (ER+) breast cancer – which makes up 80 per cent of all breast cancers.

Luca Magnani, professor of epigenetic plasticity at The Institute of Cancer Research, London, said: “After surgery to remove primary oestrogen receptor positive breast cancer, patients are given five to 10 years of hormone therapy which aims to kill any remaining cancer cells. We know that this doesn’t work for all patients though, as their breast cancer can return years, or even decades later.

“We wanted to better understand why breast cancer does return so we can hopefully find ways to stop it. Our research identified a key mechanism used by cancer cells to evade therapy by remaining in a dormant state, hibernating before they ‘wake up’ years later and begin to rapidly divide again.”

ER+ breast cancer is sensiscientists tive to the hormone estrogen, which means its cells divide and grow with the help of this hormone.

Treatment often involves a combination of different therapies and surgery, usually tailored to the patient's needs.

For their study, published in the journal Cancer Discovery, researchers looked at the role of an enzyme known as G9a.

They found that inhibiting G9a prevented cancer cells from becoming dormant and killed the cells that were already hibernating.

Dr Tayyaba Jiwani, science engagement manager at Cancer Research UK - which funded the research, said: “Breast cancer survival has doubled in the UK over the last 50 years thanks to better detection and screening, but there are still more than 11,000 deaths from this type of cancer every year.”